Siemens' gets US nod for shock wave therapy:
This article was originally published in Clinica
The US FDA has approved Siemens Medical Solutions' SONOCUR basic, a low-energy extracorporeal shock wave therapy system for treating lateral epicondylitis, a condition commonly known as tennis elbow. The company's multicentre, 114-patient, US clinical trial showed that 64% of patients treated with the system achieved at least a 50% reduction in pain at a 12-week follow-up. The trial, said the company, demonstrated that treatment with the device can provide a noninvasive alternative to surgery for patients who have failed to respond to conventional therapies.
You may also be interested in...
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.